Results 31 to 40 of about 79,208 (292)
GDNF secreted by nerves enhances PD-L1 expression via JAK2-STAT1 signaling activation in HNSCC
OncoImmunology, 2017 Programmed death ligand 1 (PD-L1) functions as a key immune inhibitory factor by binding with its receptor, programmed death 1 (PD-1), to induce immune cell dysfunction and escape of the immune system.
Chengzhong Lin +11 more
doaj +1 more source
A regulating role of the JAK2 FERM domain in hyperactivation of JAK2(V617F)
Biochemical Journal, 2010 JAK2 (Janus tyrosine kinase 2) is important for signalling through many cytokine receptors, and a gain-of-function JAK2 mutation in its pseudokinase domain, V617F, has been implicated in Philadelphia chromosome-negative myeloproliferative neoplasms. How this mutation hyperactivates JAK2 is poorly understood.
Lequn, Zhao +3 more
openaire +3 more sources
Leptin Stimulates Both JAK2-dependent and JAK2-independent Signaling Pathways [PDF]
Journal of Biological Chemistry, 2008 Leptin controls body weight by activating the long form of the leptin receptor (LEPRb). Janus kinase 2 (JAK2) is associated with LEPRb and autophosphorylates in response to leptin. JAK2 also phosphorylates LEPRb, STAT3, and multiple other downstream molecules.
Lin, Jiang, Zhiqin, Li, Liangyou, Rui
openaire +2 more sources
Therapeutic potential of JAK2 inhibitors [PDF]
Hematology, 2009 AbstractThe discovery of an activating tyrosine kinase mutation JAK2V617F in myeloproliferative neoplasms (MPNs), polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis (PMF) has resulted in the development of JAK2 inhibitors, of which several are being evaluated in phase I/II clinical studies.
openaire +2 more sources
CALR mutation profile in Irish patients with myeloproliferative neoplasms
Hematology/Oncology and Stem Cell Therapy, 2016 Insertion and/or deletion mutations of the CALR gene have recently been demonstrated to be the second most common driver mutations in the myeloproliferative neoplasms (MPNs) of essential thrombocythemia (ET) and primary myelofibrosis (PMF).
Karl Haslam +6 more
doaj +1 more source
JAK2 Variant and Parkinsonian Syndromes: Coincidence or Pathophysiological Link? [PDF]
Mov Disord Clin PractAbstract Background JAK2 variants are a hallmark of myeloproliferative neoplasms (MPNs), including polycythemia vera and essential thrombocythemia. These disorders are often associated with thrombotic and inflammatory complications. From a movement disorder perspective, chorea is a rare but well‐recognized neurological occurrence in this context ...
Jurado E +5 more
europepmc +2 more sources
Myeloproliferative neoplasms: From JAK2 mutations discovery to JAK2 inhibitor therapies
Oncotarget, 2011 Most BCR-ABL1-negative myeloproliferative neoplasms (MPN) carry an activating JAK2 mutation. Approximately 96% of patients with polycythemia vera (PV) harbors the V617F mutation in JAK2 exon 14, whereas the minority of JAK2 (V617F)-negative subjects shows several mutations in exon 12. Other mutation events as MPL, TET2, LNK, EZH2 have been described in
PASSAMONTI, FRANCESCO +3 more
openaire +4 more sources
Progressive optic neuropathy secondary to JAK2 mutation-positive myeloproliferative neoplasm
Indian Journal of Ophthalmology. Case Reports, 2022 We describe a 25-year-old male presenting with chronic papilledema due to cerebral venous sinus thrombosis (CVST) and was found to have a myeloproliferative disorder with JAK2 mutation. All measures to salvage vision were unfruitful from transverse sinus
Swetha Komma +3 more
doaj +1 more source
Regulation of the Glutamate Transporters by JAK2 [PDF]
Cellular Physiology and Biochemistry, 2011 The Janus-activated kinase-2 JAK2 is involved in the signaling of leptin and erythropoietin receptors and mediates neuroprotective effects of the hormones. In theory, JAK2 could be effective through modulation of the glutamate transporters, carriers accounting for the clearance of glutamate released during neurotransmission.
Zohreh, Hosseinzadeh +6 more
openaire +2 more sources
, 2021 It is known that chronic stress modulates multiple processes in a complex microenvironment, such as angiogenesis and immune function. However, the role of chronic stress inducing tumor angiogenesis and how it contributes to tumor progression are not ...
YanJie Lu (11276148) +11 more
core +1 more source